Expanded multi-year agreement will scale AI-powered data solutions across Pfizer’s R&D portfolio.
Campbell, CA – February 12, 2024 – Saama, a leader in artificial intelligence (AI)-enabled solutions for life sciences, has announced an expanded strategic agreement with Pfizer to further integrate AI across clinical development programs.
Building on a successful collaboration initiated in 2020, the new multi-year deal will extend the use of Saama’s Smart Data Quality (SDQ) platform—first deployed to streamline Pfizer’s COVID-19 vaccine trials—across a broader portfolio of global studies. SDQ has proven effective in automating data review processes, significantly accelerating database lock timelines.
“The success of our initial work with Pfizer showcased the speed and power of AI to transform clinical trials,” said Lisa Moneymaker, Chief Technology & Product Officer at Saama. “This expanded partnership validates the potential of our platform to modernize drug development at scale.”
Pfizer will now scale SDQ across its global research programs and also deploy Saama’s Biometrics Research and Analysis Information Network, a new solution designed to streamline statistical workflows and speed regulatory submissions. This system digitizes clinical study specifications and generates submission-ready tables, listings, and figures—cutting down the time and complexity typically involved in regulatory filings.
“Accelerating analysis and data reporting is central to faster drug development,” said Demetris Zambas, Vice President and Global Head of Data Monitoring and Management at Pfizer. “Our continued partnership with Saama will help optimize data quality and reduce the time needed for critical decision-making.”
Saama’s AI-powered platform brings together clinical trial data from diverse sources, allowing study teams to more effectively manage volume, variability, and velocity of clinical data. The platform supports real-time medical review, predictive analytics for patient behavior, and early detection of clinical signals—all aimed at improving trial efficiency and outcomes.
Saama will be showcasing its full suite of AI solutions at SCOPE Summit 2024 in Orlando, FL (Booth 813), February 11–14.
About Saama
Saama is a global technology company focused on accelerating drug development through advanced AI solutions. Its platform has powered critical clinical trials, including those leading to the first approved COVID-19 vaccine. Headquartered in California with global operations, Saama partners with leading pharmaceutical companies to drive faster, smarter R&D decisions. Learn more at www.saama.com.
By